ViroPharma Gets Good News And Bad News On Cinryze From FDA
This article was originally published in The Pink Sheet Daily
sBLA for acute angioedema treatment gets a “complete response,” putting Cinryze into the losers’ bracket contesting for the first U.S. acute HAE approval. Drug’s prophylactic labeling, meanwhile, is amended to allow self-administration.
You may also be interested in...
ViroPharma assures investors that its lead product Cinryze is growing and that launches in the EU are on track during an analyst day presentation.
With four drugs in the space, hereditary angioedema is an unusually well-served orphan disease. But the rare condition still has no clear path for efficacy assessment.
Overcoming an FDA advisory committee that expressed doubts about efficacy and potential hypersensitivity reactions and a "complete response" letter asking for a Risk Evaluation and Mitigation Strategy, Dyax won approval for Kalbitor (ecallantide) Nov. 27 to treat acute attacks of hereditary angioedema in patients 16 and older